Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cloprednol is a synthetic glucocorticoid, classified as a small molecule drug. It has been investigated primarily for the treatment of asthma and arthritis. As a glucocorticoid, cloprednol acts as an agonist at the glucocorticoid receptor, exerting anti-inflammatory and immunosuppressive effects by modulating gene expression to inhibit pro-inflammatory signals and promote anti-inflammatory pathways. Clinical studies have shown that oral cloprednol can improve control in corticosteroid-dependent asthma with fewer long-term side effects compared to other corticosteroids[1][4][5]. Its pharmacokinetics are characterized by a short serum half-life (approximately 1.8–2.7 hours), nonlinear plasma protein binding, and rapid onset of action[4][6]. The drug has also been used topically for localized inflammatory conditions such as eczema[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cloprednol.